Rights and permissions
About this article
Cite this article
Adalimumab deemed most cost-effective option in Canada. Pharmacoecon. Outcomes News 611, 6 (2010). https://doi.org/10.2165/00151234-201006110-00012
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-201006110-00012